Table 5. Effect sizes of pharmacological interventions compared with placebo using the outcome scale of CGI for patients with Tourette syndrome.
| Concomitant Drug/Study (N) | CGI | ||
|---|---|---|---|
| Author (Year) | N1 | Age2 | WMD |
| Alpha-2 adrenergic agonist agent | |||
| Clonidine | |||
| Leckman,1991 | 1 | b | -0.600(-0.996,-0.204) |
| Anticonvulsant | |||
| Levetiracetam | |||
| Smith-hicks,2007 | 1 | a | 0.090(-0.572,0.752) |
| Antipsychotic agent | |||
| Atypical Antipsychotic agent | |||
| Ziprasidone | |||
| Sallee,1999 | 1 | a | -0.700(-1.407,0.007) |
| Risperidone | |||
| Dion,2002 | 1 | b | -0.650(-1.207,-0.093) |
| CNS stimulant | |||
| Methylphenidate | |||
| Mixed dosage(0.1,0.3,0.5 mg/kg) | |||
| Gadow,1999 | 1 | a | 0.000(-0.410,0.410) |
| Gamma-aminobutyric acid-B receptor agonist | |||
| Baclofen | |||
| Singer,2001 | 1 | a | -0.900(-1.497,-0.303) |
| Glutamate agonist | |||
| N-Acetylcysteine | |||
| Bloch,2016 | 1 | a | 0.100(-0.622,0.822) |
| Selective norepinephrine reuptake inhibitor | |||
| Atomoxetine | 2 | a | -0.644(-0.910,-0.378) |
| Allen,2005 | 1 | a | -0.600(-0.957,-0.243) |
| Spencer,2008 | 1 | a | -0.700(-1.099,-0.301) |
| Smoking cessation agent plus Antipsychotic drugs | |||
| Nicotine patch plus haloperidol | |||
| Mcconville,1992 | 1 | b | -0.800(-1.901,0.301) |
| 5HT3-receptor antagonists | |||
| Metoclopramide | |||
| Nicolson,2005 | 1 | a | -1.000(-1.639,-0.361) |
Note: Significant results are in bold.
1: N:number of studies;
2: a represented that the subjects included in the study were children; b represented that the subjects included in the study were mixed participation (children and adult).